Markus Warmuth has not added Biography.
If you are Markus Warmuth and would like to personalize this page please email our Author Liaison for assistance.
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Blood Jan, 2003 | Pubmed ID: 12393636
The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.
Blood Jan, 2003 | Pubmed ID: 12393654
SRC family kinases: potential targets for the treatment of human cancer and leukemia.
Current pharmaceutical design , 2003 | Pubmed ID: 14529415
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Nature genetics May, 2004 | Pubmed ID: 15098032
An efficient rapid system for profiling the cellular activities of molecular libraries.
Proceedings of the National Academy of Sciences of the United States of America Feb, 2006 | Pubmed ID: 16492761
A general strategy for creating "inactive-conformation" abl inhibitors.
Chemistry & biology Jul, 2006 | Pubmed ID: 16873026
Ba/F3 cells and their use in kinase drug discovery.
Current opinion in oncology Jan, 2007 | Pubmed ID: 17133113
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
Proceedings of the National Academy of Sciences of the United States of America Jan, 2007 | Pubmed ID: 17185414
B-Raf kinase inhibitors for cancer treatment.
Current opinion in investigational drugs (London, England : 2000) Jun, 2007 | Pubmed ID: 17621874
Essential role of stromally induced hedgehog signaling in B-cell malignancies.
Nature medicine Aug, 2007 | Pubmed ID: 17632527
Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.
Annals of hematology Nov, 2007 | Pubmed ID: 17668209
Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Annals of hematology Mar, 2008 | Pubmed ID: 17960378
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
Bioorganic & medicinal chemistry letters Nov, 2008 | Pubmed ID: 18667312
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
Cancer cell Sep, 2008 | Pubmed ID: 18772113
A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function.
Molecular cell Jan, 2009 | Pubmed ID: 19150426
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.
Nature Jan, 2010 | Pubmed ID: 20072125
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Biochimica et biophysica acta Mar, 2010 | Pubmed ID: 20152788
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.
Cancer research Jul, 2010 | Pubmed ID: 20530672
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
Journal of medicinal chemistry Aug, 2010 | Pubmed ID: 20604564
The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease.
Cancer research Aug, 2010 | Pubmed ID: 20670954
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Science translational medicine Sep, 2010 | Pubmed ID: 20881279
Hedgehog pathway activation in chronic myeloid leukemia.
Cell cycle (Georgetown, Tex.) Sep, 2010 | Pubmed ID: 20928937
Allosteric inhibition of BCR-ABL.
Cell cycle (Georgetown, Tex.) Sep, 2010 | Pubmed ID: 20930519
Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.
Nature medicine Dec, 2010 | Pubmed ID: 21076395
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Cancer research Apr, 2011 | Pubmed ID: 21324920
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.
Nature genetics Oct, 2011 | Pubmed ID: 21892161
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2011 | Pubmed ID: 21949247
Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.
Blood Jan, 2012 | Pubmed ID: 22130798
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature Mar, 2012 | Pubmed ID: 22460905
Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies.
Expert opinion on drug discovery Aug, 2008 | Pubmed ID: 23484970
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.
Journal of medicinal chemistry Jul, 2013 | Pubmed ID: 23742252
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.
ACS medicinal chemistry letters Jun, 2010 | Pubmed ID: 24900187
Profiling the kinome for drug discovery.
Drug discovery today. Technologies , 2006 | Pubmed ID: 24980528
NAMPT is the cellular target of STF-31-like small-molecule probes.
ACS chemical biology Oct, 2014 | Pubmed ID: 25058389
Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.
Organic letters Nov, 2014 | Pubmed ID: 25376106
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3? Splice Site Selection through Use of a Different Branch Point.
Cell reports Nov, 2015 | Pubmed ID: 26565915
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados